Julphar launched Julmentin ES in Jordan

During a scientific lecture held at Le Royal Hotel Amman on March 13th, Julphar’s Pediatric Primary Care announced the launch of Julmentin ES in Jordan. The product launch is part of the company’s commitment to work towards a healthier community and a better quality of life for children and their families.
During the scientific session, Dr. Wail Hyajneh, Dean of the School of Medicine at the Jordan University of Science and Technology (JUST), and Associate Professor of Pediatric Infectious Diseases, gave a lecture on the latest guidelines and management of pediatric acute otitis media to an audience of over 100 invited physicians. The lecture featured an interactive and informative session, and covered best practices sharing and discussion on the latest updates in pediatrics.
Julmentin ES (642.9 mg/5ml Co-Amoxiclav) is used for the treatment of acute otitis media, and especially developed for the recurrent or persistent middle ear infections. It is the latest addition to the Julmentin portfolio in Jordan.